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Quantitative Human Immunodeficiency Virus (HIV)-1 
Antibodies Correlate With Plasma HIV-1 RNA and  
Cell-associated DNA Levels in Children on Antiretroviral 
Therapy
Margaret McManus,1,  Jennifer Henderson,1 Anita Gautam,1 Robin Brody,1 Eric R. Weiss,1 Deborah Persaud,2 Eric Mick,3 and Katherine Luzuriaga1; and  
the PACTG 356 Investigatorsa 
1Program in Molecular Medicine, University of Massachusetts Medical School, Worcester; 2Department of Pediatrics, Division of Infectious Diseases, Johns Hopkins University School of Medicine, 
Baltimore, Maryland; and 3Department of Quantitative Health Sciences, University of Massachusetts Medical School, Worcester
Background. This study measured serial plasma human immunodeficiency virus (HIV)-1–specific antibody (Ab) levels in chil-
dren who initiated antiretroviral therapy (ART) prior to 2 years of age, and evaluated their relationship to peripheral blood HIV-1 
RNA and DNA levels.
Methods. We studied 46 HIV-1–infected children, stratified by age at ART initiation (<3 mo, early therapy [ET]; >3 mo–2 years, 
late therapy [LT]) and by virologic response (R) or non-response (NR), before and up to 4 years following ART. We studied 20 
HIV-1–uninfected children born to HIV-1–infected mothers (seroreverters [SR]) as controls. Plasma immunoglobulin G (IgG) Ab 
levels directed against HIV-1 envelope (gp160, gp41), gag (capsid, p24; matrix, p17), reverse transcriptase (p66/51), and integrase 
(p31) were serially measured using quantitative enzyme-linked immunosorbent assays. HIV-1 Ab rates of decline were estimated 
over the first 15 months of the study.
Results. The HIV-1 Ab rates of decline in the ET-R group were similar to those in the SR group for all Ab specificities, except for 
p17 (P = .01). Ab decline rates in the LT-R group and the NR group were significantly slower than in the SR group for all tested Ab 
specificities. After 1 year of age, Ab levels to p31 and p17 were significantly associated with HIV-1 RNA levels (P < .001); Ab levels to 
gp160 (P < .001) and gp41 (P < .001) were significantly associated with cell-associated HIV-1 DNA levels.
Conclusions. Quantitative HIV-1–specific Ab levels may be useful for screening children on ART for viral suppression or for 
residual, cell-associated HIV-1 DNA levels.
Clinical Trials Registration. NCT00000872.
Keywords. pediatric early antiretroviral therapy; HIV-1 persistence; HIV-1 quantitative antibodies.
Combination antiretroviral therapy (ART) markedly reduces 
human immunodeficiency virus (HIV)-1–related morbidity 
and mortality in children [1]. Early ART initiation in chil-
dren prior to 3–6 months of age can be particularly effective 
for long-term control of HIV-1 replication, preserving im-
mune functions [2, 3], reducing HIV-1–related illnesses and 
mortality [4], and limiting residual HIV-1 reservoirs [5, 6]. 
International treatment guidelines [7–9] now recommend 
ART initiation in HIV-1–infected children as soon as possible 
after birth.
Methods for quantifying plasma HIV-1 RNA and peripheral 
blood mononuclear cell (PBMC)-associated HIV-1 DNA 
in children following ART are expensive and logistically 
challenging, particularly for implementation in limited-
resource settings. We [10] and others [11–13] have previously 
shown that children who achieve durable suppression of HIV-1 
replication after early (<3 months) ART have very low levels of 
PBMC-associated HIV-1 DNA, and the majority lack persistent 
HIV-1 immunoglobulin G  (IgG) antibodies [3, 14]. Children 
who initiate treatment after 3–6  months of age have higher 
levels of PBMC-associated HIV-1 DNA and remain HIV-1–
antibody (Ab) positive. In a prior cross-sectional study, children 
with negative or indeterminate Western blots had lower levels 
of circulating HIV-1 DNA than those with positive Western 
blots [15]. We therefore undertook this study to further evaluate 
the utility of using quantitative HIV-1 Ab levels to HIV-1 
proteins as a screening method for virologic suppression and 
residual PBMC-associated HIV-1 DNA in children on therapy. 
The quantitation of Ab levels to selected HIV-1 proteins prior 
to and sequentially up to 4  years following ART allowed for 
the calculation of Ab clearance rates and the development of 
models that used specific Ab levels to predict the likelihood 
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of undetectable plasma HIV-1 RNA or the level of circulating, 
PBMC-associated HIV-1 DNA.
METHODS
Study Cohort
The study cohort included 46 HIV-1–infected children, stratified 
by timing of ART initiation (early therapy [ET] <3 months of age; 
late therapy [LT] >3 months to 2 years of age) and as virologic 
responders (R) or non-responders (NR). There were 44 children 
that received ART through an open-label, phase I/II clinical trial 
that evaluated the pharmacokinetics, safety, and antiviral activ-
ity of combination antiviral therapies initiated under 2 years of 
age (Pediatric AIDS Clinical Trials Group Protocol [PACTG] 
356; clinical trials NCT00000872 [16]); 2 were treated by open 
prescription. Specimens were collected from HIV-1–infected 
participants from 1995 through 2005 at clinical sites through-
out the United States and Puerto Rico. Virologic responders 
were defined as HIV-1–infected children who achieved plasma 
HIV-1 RNA levels of <400 copies/ml by 48 weeks of therapy and 
sustained plasma HIV-1 RNA <50 copies/ml through at least 96 
weeks; 4 children who were classified as responders experienced 
a viral rebound (RNA > 50 copies/ml) and 1 child experienced 
a viral blip (a single value of 106 copies/ml) after 96 weeks on 
ART. Ab decline estimates in virologic responders were calcu-
lated from samples obtained prior to 96 weeks of study. Virologic 
non-responders (NR: 10 ET and 14 LT) were children who did 
not achieve undetectable viral loads within the first year of ART 
(n = 19) or who initially suppressed viral replication but expe-
rienced a virologic rebound between 48 and 96 weeks of ART 
(n = 5). HIV-1–infected children were studied prior to ART ini-
tiation and at 6 months, 1 year, 2 years, and 4 years following 
ART initiation. We studied 20 HIV-1–uninfected children born 
to HIV-1–infected women (seroreverters [SR]), with samples 
obtained at birth and at 6 months, 1 year, and 2 years of age; the 
study of SR beyond 2 years of age was not possible, since they 
were discharged from routine follow-up for HIV-1 infection if 
found to be uninfected by 2 years of age. Institutional Review 
Boards at the University of Massachusetts Medical School and 
at each clinical site approved this study, and informed consent 
was obtained from the children’s guardians prior to enrollment.
Quantitation of HIV-1–specific Antibodies
Ab levels to HIV-1 envelope (gp160, gp41), gag (capsid, p24; 
matrix, p17), reverse transcriptase (RT; p66/51), and inte-
grase (p31) were quantified in acid citrate dextrose, heparin, 
or ethylenediaminetetraacetic acid-anticoagulated plasma 
(Becton-Dickinson Vacutainers, Mountain View, California) by 
enzyme-linked immunosorbent assay (ELISA) [17]. The 12-well 
high-binding ELISA strips were coated with recombinant pro-
teins: 10ng p24 (Immune Tech, New York, New York) or p17 
(Abcam, Cambridge, United Kingdom); or 12.5ng p31 (Abcam), 
gp41 (Abcam), gp160 (My Biosource, San Diego, California), or 
RT (Avioq, Research Triangle Park, North Carolina). The 5-point 
standard curves were prepared by serially diluting known quan-
tities of HIV-1 p24, gp41, gp160, and RT polyclonal antibodies 
(ImmunoDx, Woburn, Massachusetts) in sample buffer. The lack 
of available reliable human anti-p17 or anti-p31 mono- or poly-
clonal antibodies precluded the generation of standard curves for 
these proteins. Individual ELISA assays were performed on 1:100 
dilutions of pooled plasma samples from HIV-positive (positive 
control) and HIV-negative (negative control) individuals, as 
well as from the study cohort; in the event that a 1:100 dilution 
value fell outside the standard curve linear range, additional 1:10, 
1:1000, or 1:10 000 dilutions were run. Absorbance at 405  nm 
was measured (Biotek, Winooski, Vermont) and samples were 
considered positive if their optical densities (OD) were greater 
than 2 standard deviations from the mean OD of a pooled, HIV-
negative control (run in triplicate). Quantitative measures of p24, 
gp41, gp160, and RT antibodies were determined by extrapola-
tion of OD measurements of standard curve values. Results for 
p17 and p31 are reported as OD405nm values, since standard curves 
were not generated for these proteins. This approach resulted in 
limits of detection (LODs) (dynamic ranges), as follows: p24, 0.1 
ug/ml (0.15–125 000ug/ml); gp41, 0.4 ug/ml (0.6–50 000ug/ml); 
gp160, 0.1 ug/ml (0.2–50 000ug/ml); RT, 0.1 ug/ml (0.2–3100ug/
ml); p31, 0.06 OD405nm (0.299–2.000 OD405nm); p17, 0.06 
OD405nm (0.152–2.000 OD405nm). The lower limit of the 
dynamic range was used as the lowest possible value in all cal-
culations. Assay validation using positive controls, negative con-
trols, and individual plasma samples from 5 HIV+ individuals 
(20 total samples) showed 90% reproducibility.
Quantitation of Viral Replication and HIV-1 DNA Persistence
Plasma HIV-1 RNA loads were measured using either the Roche 
Standard (LOD <400 copies/ml) or UltraSensitive (LOD <50 cop-
ies/ml) AMPLICOR HIV-1 MONITOR kits Version 1.5 (Roche 
Diagnostics, Indianapolis, Indiana). PBMC HIV-1 total DNA 
levels were quantified just prior to initiation of ART and yearly 
for 4 years in 21 viral responders and in 8 viral non-responders, 
as previously described [10].
Statistical Analyses
Analyses used the software Stata (v13, StataCorp). We used 
a 1-way analysis of variance with a post hoc Sidak to com-
pare group Ab levels. Correlations were calculated using the 
Spearman rho. Repeated HIV-1–specific Ab levels collected 
longitudinally were tested with linear mixed-regression 
models to estimate the relative decline rates in each group 
through 15  months (data through 12  months with a sam-
ple window of 3  months; mean of 3 data points per partici-
pant). Post-estimation contrasts compared the decline rates 
between groups. Generalized linear models (ordinary least 
squares regression for continuous data and logistic regression 
for binary outcomes) were fit to test for the association of Ab 
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levels with plasma HIV-1 RNA copies/ml or HIV-1 DNA cop-
ies per million PBMC, using samples obtained at >12 months 
of age and adjusting for potentially-confounding covariates. 
Regression coefficients were plotted with coefplot [18]. All sta-
tistical tests were 2-sided; P <  .05 was considered statistically 
significant.
RESULTS
Study Cohort
We studied 66 children aged 0 to 24 months, who were grouped 
by HIV-1 infection status, age at ART initiation (ET or LT), 
and response to ART (responder or non-responder; Table  1). 
There was no difference in the log baseline HIV-1 RNA levels 
between the ET-R, LT-R, and NR groups (medians 5.4, 4.8, and 
5.5, respectively; P =  .6). The log HIV-1 DNA at baseline was 
similar across the ET-R, LT-R, and NR groups (medians 3.0, 3.7, 
and 3.8, respectively; P = .4).
Baseline Antibody Levels
Baseline anti-gp160, -RT, -p24, and -p17 Ab levels were similar 
across all groups (Table 2). Baseline anti-gp41 Ab levels were 
significantly higher in the SR group than in the ET-R, LT-R, and 
NR groups (P = .002); baseline anti-p31 Ab levels were signifi-
cantly higher in the SR group than in the LT-R (P = .008) and NR 
(P = .04) groups. Baseline age was inversely correlated with Ab 
levels to RT (rho = 0.34, P = .007), gp41 (rho = -0.35, P = .005), 
p31 (rho = -0.45,P < .001), and p17 (rho = -0.26,P = .04). Baseline 
gp160 and gp41 Ab levels were highly correlated (rho = 0.68; 
P  <  .001). In young children with continued HIV-1 replica-
tion, Ab levels to gp160 and gp41 initially appeared to decrease 
from baseline until around age 4–5 months, after which levels 
increased (data not shown).
Plasma HIV-1 Antibody Clearance Rates in HIV-1–uninfected Infants
We measured HIV-1 Ab in serial plasma samples from HIV-1–
uninfected infants born to HIV-1–infected women in order to 
estimate the decay rates of passively-acquired maternal anti-
bodies and to estimate the time to clearance from the circu-
lation. The decline rate in gp41-specific Ab was faster (-0.25 
log ug/ml /month) than in all other Ab specificities (Table 2). 
Using the model estimates for the Ab decline in the SR group, 
the estimated time to clearance of maternal Ab in the absence 
of an HIV-1 infection was calculated to be 10.9  months for 
p17, 11.7  months for p31, and 12.4–12.9  months for gp160, 
RT, gp41, and p24 (Table 2). Time estimates are based on the 
model parameters and do not suggest that all SR were negative 
by the estimated time, but rather approximate the time when 
the model fit crossed the assay cutoff.
Plasma HIV-1 Antibody Decay Rates in HIV-1–infected Children on 
Antiretroviral Therapy
Over the first 15 months of the study, HIV-1 Ab decline rates in 
the ET-R group were similar to the SR group for all Ab specific-
ities, with the exception that the decline rate of p17 Ab levels in 
ET-R group was slower than in the SR group (P = .01; Table 2, 
Figure 1). The estimated time to clearance of all antibodies in 
ET-R varied by specificity, and ranged from 12 to 21 months 
(Table 2). The estimated age at the clearance of antibodies in 
ET-R was similar to the estimated age of clearance for the SR 
for all specificities, except for p24 (20.6 months vs 12.9 months, 
respectively) and p17 (16.6  months vs 10.9  months, respec-
tively). By contrast, Ab decline rates in the LT-R group and the 
NR group were significantly different (slower decline or no de-
cline) from the SR group for all tested Ab specificities (P < .001 
for all comparisons). Ab decline rates in the LT-R group and 
the NR group were significantly different from the ET-R group 
for most Ab specificities (P < .001); an exception was that the 
Table 1. Study Cohort at Baseline: Pre-therapy Viral Load, CD4 Percentage, and Therapeutic Regimens
Cohort SeroReverters ET Respondersa LT Respondersa Non-responders
n 20 14 8 24
Age, mos 0 (0–0) 1.8 (1.4–2.3) 9.5 (5.7–13.4) 3.8 (2.6–7.5)
log10 plasma HIV-1 RNA, 
copies/ml
N/A 5.4 (5.2–5.6) 4.8 (4.7–5.7) 5.5 (4.7–6.0)
log10 proviral DNA,  
copies/million PBMCs
N/A 3.0 (2.7–3.4)
n = 13
3.7 (3.0 - 4.0)
n = 8
3.8 (3.5–3.9)
n = 8
CD4 % 49
(43–59)
38 (28 - 48) 35 (27 - 42) 35 (27–46)
Therapeutic regimens N/A 10 (2 NRTIs + 1 NNRTI + 1 PI)  
2 (3 NRTIs + 1 NNRTI)  
1 (2 NRTIs + 1 NNRTI)
5 (2 NRTIs + 1 NNRTI + 1 PI)  
2 (3 NRTIs + 1 NNRTI)  
1 (2 NRTIs + 1 NNRTI)
8 (2 NRTIs + 1 NNRTI + 1 PI) 
7 (3 NRTIs + 1 NNRTI)  
9 (2 NRTIs + 1 NNRTI)
Age in mos at viral 
suppression
N/A 4.3 (3.5–5.6) 14.8 (8.4–21.7) N/A
Values are provided as medians with 25th and 75th percentiles (interquartile range).
Abbreviations: ART, antiretroviral therapy; ET, early therapy; HIV, human immunodeficiency virus; LT, late therapy; N/A, not applicable; NNRTI, non-nucleoside reverse-transcriptase inhibitor; 
NRTI, nucleoside reverse transcriptase inhibitor; PBMC, peripheral blood mononuclear cell; PI, protease inhibitor.
aResponders were defined as study subjects who achieved a viral load of <400 copies/ml by 48 weeks of ART therapy and whose peripheral blood HIV-1 RNA levels remained under assay 
detection limits through 4 years of ART.
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p17-specific Ab decline in the LT-R and ET-R groups were sim-
ilar (P = .28), while the p17 Ab decay rate in the NR was sig-
nificantly slower than in the ET-R group (P = .001). Ab levels 
in the NR group did not decline, with estimated slopes near 0 
(Table 2, individual points for the NR group not displayed in 
Figure 1). There were 4 children who initially suppressed HIV-1 
replication, experienced a rebound in their viral loads after 96 
weeks of ART, and also experienced a rebound in all Ab levels 
(data not shown).
Association of Quantitative Antibody Levels With Plasma HIV-1 RNA 
Levels and Circulating Cell–associated HIV-1 DNA Levels
We used a linear regression model to predict HIV-1 RNA using 
Ab levels obtained after 12 months of age for each HIV-1 spec-
ificity tested, except gp41 (highly correlated to gp160): adjust-
ing for age accounted for 62% of the variance in HIV-1 RNA 
(F[6,134] = 36; P < .001; R2 = 0.62). Ab levels to gp160, p31, 
and p17 were significant predictors in the model (Figure 2). 
Ab levels to p31 and p17 were associated with higher plasma 
HIV-1 RNA levels (F[3,138]  =  66; P  <  .001; R2  =  0.59; 
p31  β  =  0.95; p17  β  =  0.84), and a logistic model estimated 
that a unit increase in p31 Ab was associated with a 14-fold 
increase in the odds of an RNA level >50c/ml (P < .001). The 
estimated probability of detectable HIV-1 RNA based on Ab 
levels of p31, derived from the logistic regression model, is 
shown in Figure 2.
A model developed to predict circulating HIV-1 DNA lev-
els using Ab specificities, excluding gp41 and adjusting for age, 
accounted for 41% of the variance in HIV-1 DNA (F[6,61] = 7.1; 
P <  .001; R2 = 0.41, Figure 2). In children over 12 months of 
age, gp160 Ab levels predicted circulating HIV-1 DNA levels 
(F[2,65], P < .001; R2 = 0.37; β = 0.51). A logistic model using 
gp160-specific Ab levels estimated that each unit increase in a 
log gp160 Ab was associated with a 6-fold increase in the odds 
of an HIV-1 DNA level >1000 (P < .001). The estimated prob-
ability of an HIV-1 DNA level > 1000 copies/million PBMC 
based on Ab levels of gp160 derived from the logistic regression 
model is shown in Figure 2.
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Figure 1. Human immunodeficiency virus (HIV)-1–specific antibody (Ab) decay rates in HIV-1–uninfected infants born to HIV-1–infected women (SR) in ET-R and LT-R groups. 
Quantitative (Quant) Ab levels of HIV-1 gp160, gp41, RT, p24, p31, and p17 in SR, ET-R, and LT-R children over the first 24 months of age. Ab decline rates, calculated over 
the first 15 months, in the ET-R group are similar to the SR group for all Ab specificities, except for p17 (P = .01). Fitted lines for the SR and ET-R groups were calculated with 
parameters from the linear mixed effects model. SR are shown as blue circles; ET-R as red squares; and LT-R as black, hollow squares. Abbreviations: Ab, antibody; ET, early 
therapy; HIV, human immunodeficiency virus; LT, late therapy; OD, optical densities; Quant, quantitative; R, viral responders; SR, seroreverters.
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DISCUSSION
We and others have previously shown that ART initiation in chil-
dren prior to 3–6 months of age allows for the long-term control 
of HIV-1 replication and limits residual HIV-1 reservoirs [5, 6]. 
Younger ages at ART initiation, more intense ART regimens, and 
the absence of resistance mutations were related to virologic sup-
pression [16]. Children who rapidly suppress HIV-1 replication 
after early (<3 months) ART initiation commonly lack persistent 
HIV-1–specific Ab responses [3, 12, 14] and have lower circulat-
ing HIV-1 DNA levels [3, 10, 11, 19]. We have previously reported 
lower PBMC-associated HIV-1 DNA levels in early-treated, viral-
ly-suppressed children with negative or indeterminate Western 
blots [15]. Using data and repository samples from a well-charac-
terized early ART cohort [16], we evaluated whether quantitative 
HIV-1 Ab levels might predict levels of HIV-1 RNA and DNA in 
children on ART.
Because maternal IgG antibodies are passively transferred 
from women to their infants during the last trimester of preg-
nancy [20, 21], all children born at term to HIV-1–infected 
women are seropositive. Baseline age correlated inversely with 
Ab levels. Moreover, HIV-1–infected children who initiated 
ART prior to 3 months of age and who suppressed viral replica-
tion by 48 weeks experienced Ab decline rates similar to those 
in uninfected children born to HIV-1–infected women for all 
Ab specificities, except p17. This suggests little de novo IgG pro-
duction by the infant over the first several months of age. From 
these data, it is difficult to determine exactly when de novo Ab 
production to HIV-1 proteins begins; however, baseline Ab data 
over the range of ages studied (0–24 months) demonstrate an 
increase in antibodies to gp160 and gp41 at around 4–5 months 
of age (data not shown), suggesting the active production of 
these antibodies. In contrast, antibodies to most HIV-1 proteins 
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Figure  2. Prediction of human immunodeficiency virus (HIV)-1 RNA and DNA based on linear and logistic models using quantitative antibody levels as predictors. 
A, Coefficient plot: coefficients and the 95% confidence intervals for the antibody (Ab) specificities, derived from a linear regression model predicting HIV-1 RNA levels (c/ml) 
from Ab levels. Bars which do not cross the line at 0 indicate a significant predictor. Model results: F(6,134) = 36; P < .001; R2 = 0.62. B, The estimated probability of detectable 
HIV-1 RNA (>50 c/ml) based on Ab levels of p31 derived from the logistic model. C, Coefficient plot: coefficients and the 95% confidence interval for the Ab specificities, 
derived from a linear regression model predicting HIV-1 DNA levels (c/million peripheral blood mononuclear cell) from Ab levels. Bars which do not cross the line at 0 indi-
cate a significant predictor. Model results: F(6,61) = 7.1; P < .001; R2 = 0.41. D, The estimated probability of HIV-1 DNA > 1000 based on Ab levels of gp160 derived from the 
logistic model. Abbreviations: Ab, antibody; ELISA, enzyme-linked immunosorbent assay; HIV, human immunodeficiency virus; OD, optical densities; PBMC, peripheral blood 
mononuclear cell; Pr, probability; RT, reverse transcriptase.
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are detected in adults within 3–4 weeks of infection; antibod-
ies to p31 take longer and are produced around 7 weeks after 
detectable viremia [22]. The apparent delay in the robust pro-
duction of HIV-1 antibodies in infants, despite high levels of 
HIV-1 replication in early infections, is notable, and could be 
due to a lack of CD4+ T-cell help in the face of high levels of 
HIV-1 replication.
In our study, most HIV-1–uninfected children born to 
HIV-infected women cleared maternal antibodies at around 
13 months of age, although prior reports indicate that passive-
ly-transferred maternal antibodies may persist in the circula-
tion of uninfected infants up to 18 months [23, 24]. Our data 
suggest that antibodies detected after 12–13 months of age are 
largely generated in response to the viral replication and antigen 
production associated with infection.
In untreated HIV-1–infected adults, anti–HIV-1 Ab levels are 
stable over time and correlate with viral loads [25]. Anti–HIV-1 
Ab levels decline but do not totally clear with the suppression 
of HIV-1 replication on ART; higher levels of HIV-1–specific 
antibodies on suppressive therapy are associated with later 
initiations of ART after infection and with higher cell-associ-
ated DNA and RNA levels. HIV-1–specific Ab persistence after 
virologic suppression on ART may be stimulated by low levels 
of ongoing viral replication or the production of translational-
ly-competent HIV-1 transcripts [26].
Our study suggests that in children older than 1  year of age, 
anti-p31 and anti-p17 IgG Ab levels may be good markers for ongo-
ing replication, while Ab levels to gp160 could serve as a marker for 
PBMC-associated HIV-1 DNA levels. In adults, Lee and colleagues 
reported that anti-p17 Ab levels were associated with integrated 
HIV-1 DNA levels in resting CD4+ T-cells [27]. A recent pediatric 
study that examined the relationship between anti-gp41 antibodies 
and peripheral blood HIV-1 DNA levels found that lower levels of 
antibodies were associated with a younger age at ART initiation; 
however, there was no significant correlation between anti-gp41 
Ab levels and peripheral blood HIV-1 DNA levels [28]. The differ-
ence in findings between the latter study and ours may be related to 
the older age at ART initiation (median age 3.3 years) in that study, 
or the different methods used to quantitate the total cell-associated 
HIV-1 DNA levels.
Our study included a relatively small number of children 
from the United States and Puerto Rico who initiated ART 
within 2 years of birth. The results of the prediction models may 
be limited to children who initiate ART relatively soon after pri-
mary infection, and may not be broadly applicable to all HIV-1–
infected children. We used previously-measured cell-associated 
HIV-1 DNA levels and only had HIV-1 DNA data for a limited 
number (8) of non-responders; nevertheless, we expect that the 
inclusion of a larger number of children with detectable vire-
mia, high HIV-1 DNA levels, and relatively high Ab levels would 
further strengthen the observed association. Larger studies that 
include participants with more diverse ages at ART initiation 
and various HIV-1 subtypes will be important to more gener-
ally evaluate the utility of HIV-1 Ab levels as markers for viral 
replication and reservoir size. Due to the limited blood volumes 
available, we did not include other factors, such human leuko-
cyte antigen genotyping, which have been reported to influence 
the generation of antibodies following early ART therapy [29]. 
A recent study suggests that HIV-specific IgG3 antibodies may 
be predictors of spontaneous controllers [30]. We did not inves-
tigate IgG subclasses, but doing so may elucidate specific com-
binations of IgG subclasses that might be good markers for viral 
replication or persistence.
In summary, even with these limitations, our data suggest 
that HIV-1–specific Ab levels may be useful markers for screen-
ing children on ART for viral suppression or for low residual 
cell-associated HIV-1 DNA levels. This may be particularly use-
ful for screening early-treated children on ART for therapeutic 
vaccines and other protocols aimed at achieving HIV-1 remis-
sion. Since the measurement of quantitative HIV-1 Ab levels 
requires small blood volumes and is generally more rapid, less 
expensive, and less technically-intensive than the measurement 
of HIV-1 nucleic acids, the measurement of quantitative anti-
bodies may also be useful for screening for virologic suppres-
sion and HIV-1 DNA persistence in early-treated children in 
limited-resource settings.
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